title: Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature.
abstract: The patient, a 79-year-old Japanese man, was diagnosed with the chronic phase of chronic myeloid leukemia and begun on nilotinib therapy in April 2011. The therapeutic response was major molecular response in August. About 19 months after the start of nilotinib therapy at 400 mg/day (November 2012), an adenocarcinoma (24 x 20 mm) confined to the head of the pancreas developed. In February 2013, a pancreaticoduodenectomy was performed. The therapy regimen was switched to dasatinib at 100 mg/day, beginning in April. The response was still major molecular response with no recurrence of pancreatic carcinoma in July 2013. There have been 29 reported cases of secondary neoplasms associated with nilotinib therapy. These secondary neoplasms were characterized by relatively frequent occurrence of papilloma (6 cases), gastric cancer (3 cases), fibroma (3 cases), and thyroid neoplasms (2 cases). The present case, however, is the first to be reported as carcinoma of the pancreas. This report describes the case.
authors.affiliation: Juntendo University Faculty of Medicine, Urayasu Hospital, Clinic of Hematology, Urayasu, Japan Phone: 047-353-3111 E-mail: yasu_sek@juntendo-urayasu.jp.
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Sekiguchi
authors.forename: Asami
authors.initials: A
authors.lastname: Shimada
authors.forename: Moe
authors.initials: M
authors.lastname: Matsuzawa
authors.forename: Hidenori
authors.initials: H
authors.lastname: Imai
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Wakabayashi
authors.forename: Keiji
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Noriko
authors.initials: N
authors.lastname: Nakamura
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Sawada
authors.forename: Junichi
authors.initials: J
authors.lastname: Arita
authors.forename: Norio
authors.initials: N
authors.lastname: Komatsu
authors.forename: Masaaki
authors.initials: M
authors.lastname: Noguchi
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced* / Q000453:epidemiology / Q000601:surgery; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D015984:Causality; D002986:Clinical Trials as Topic; D000069439:Dasatinib / Q000627:therapeutic use; D003863:Depression / Q000139:chemically induced; D057915:Drug Substitution; D005350:Fibroma / Q000453:epidemiology; D006391:Hemangioma; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000097:blood / Q000188:drug therapy*; D008113:Liver Neoplasms; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology* / Q000601:surgery; D010190:Pancreatic Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000601:surgery; D016577:Pancreaticoduodenectomy; D010195:Pancreatitis / Q000139:chemically induced; D010212:Papilloma / Q000453:epidemiology; D011743:Pyrimidines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000453:epidemiology; D013964:Thyroid Neoplasms / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; C498826:nilotinib; D000069439:Dasatinib